Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

Preoperative Transhepatic Arterial Chemotherapy in the Treatment of Liver Metastasis of Resectable Colorectal Cancer

The purpose of this study is to investigate whether preoperative TAC is able to improve progression free survival and overall survival in patients receiving liver metastasis resection of colorectal cancer.

We administered TAC(oxaliplatin,FUDR and MMC) 7 days before liver metastasis resection of colorectal cancer. The study endpoints were progression free survival and overall survival as evaluated by intent-to-treat analysis.

Inclusion Criteria:

• age <= 75 years
• resectable liver metastasis
• remnant liver volume >= 70%
• without other organ metastasis or peritoneum metastasis
• without contradiction of cardiac and pulmonary diseases

Exclusion Criteria:

• age > 75 years
• unresectable liver metastasis
• remnant liver volume < 50%
• with other organ metastasis or peritoneum metastasis
• with contradiction of cardiac and pulmonary diseases